Transient eruptive keratoacanthomas associated with nivolumab

Nina K. Antonov, MD, Kesav G. Nair, MD, and Charles L. Halasz, MD
New York, New York and Norwalk, Connecticut

Key words: apocrine adenocarcinoma; checkpoint inhibitors; eruptive keratoacanthomas; nivolumab; programmed cell death 1 inhibitor.

INTRODUCTION
Programmed cell death 1 (PD-1) inhibitors show efficacy in the treatment of metastatic melanoma, non–small cell lung cancer, urothelial cancers, head and neck squamous cell carcinoma, cervical cancer, and various malignancies with microsatellite instability and high tumor mutational burden. PD-1 inhibitors are reported in association with various cutaneous adverse effects including lichenoid eruption, eczema, vitiligo and bullous pemphigoid.1,2 The development of keratinocyte neoplasms such as actinic keratosis, seborrheic keratosis, basal cell carcinoma, and squamous cell carcinoma have also been reported.1 A recent review of dermatologic toxicities associated with immune checkpoint blockade suggested they be divided into 4 categories: inflammatory, immunobullous, alteration of keratinocytes, and alteration of melanocytes.3 We report a case of eruptive keratoacanthomas (KAs) seen in association with nivolumab therapy, which resolved without intervention and despite continuation of immunotherapy.

CASE REPORT
A 92-year-old man with axillary apocrine adenocarcinoma presented to his dermatologist with new crusted lesions on the arms. Eight months prior, the patient had a painful mass in his right axilla with adjacent lymphadenopathy. Pathology findings of the cutaneous mass showed small glandular structures filling the dermis and infiltrating the subcutaneous tissue and showed pagetoid involvement of the epidermis. Pathology findings of the lymph node were consistent with metastatic apocrine carcinoma. Tumor cells were positive for periodic acid–Schiff and mucicarmine and negative for cytokeratin 20, thyroid transcription factor 1, and napsin A. Genomic studies showed the tumor to be negative for human epidermal growth factor receptor 2 (immunohistochemistry 1 positive; fluorescent in situ hybridization negative), epidermal growth factor receptor mutation, and PD ligand 1. Positron emission tomography scan found enlarged hypermetabolic right axillary and mediastinal lymph nodes. Fine-needle aspiration of the mediastinal nodes via endobronchial ultrasound scan confirmed metastatic disease. In view of the patient’s advanced age, his refusal to participate in clinical trials, and paucity of effective chemotherapeutic agents for this entity, treatment with nivolumab was started after obtaining informed consent.

The patient reported that new lesions on the arms first appeared shortly after his third nivolumab infusion. On physical examination there were scattered inflamed keratotic papules on the left arm and left dorsal hand (Fig 1, A). Currette biopsy of a representative lesion showed squamous cell carcinoma, KA type (Fig 2). At his follow-up appointment 2 weeks later, the patient had more lesions, now with greater than 20 keratotic papules and plaques on the bilateral arms and dorsal hands. The largest lesion was treated with complete curettage, and pathology findings were consistent with squamous cell carcinoma. Per patient report, he subsequently had several similar-appearing lesions on the legs. At his
follow-up visit 6 weeks later, there was complete resolution of all lesions (Fig 1, B). Nivolumab treatment was continued, and the patient did not use any topical or systemic medications for his skin lesions.

**DISCUSSION**

Eruptive keratoacanthomas are a recently described and rare cutaneous side effect of PD-1 inhibitors (Table I). Ten cases have been reported, including 4 associated with pembrolizumab and 6 associated with nivolumab. Affected patients have had various metastatic malignancies including melanoma, head and neck squamous cell carcinoma, pancreatic cancer, renal cell carcinoma, and apocrine adenocarcinoma. Timing of onset of eruptive KAs has ranged from 1 to 18 months after initiation of PD-1 inhibitor therapy, with a mean of 5.5 months. Although suggested to represent a delayed onset dermatologic adverse effect,

Fig 1. A, At time of initial presentation to the dermatologist, with many inflamed keratotic papules on the left arm and hand. B, At follow-up visit 8 weeks after initial presentation, with resolution of keratotic lesions.

Fig 2. A, A curette biopsy of a representative keratotic lesion shows fragments of an atypical squamous proliferation with a crateriform invagination (hematoxylin and eosin, ×4). B, Higher power shows an atypical squamous proliferation. (A and B, Hematoxylin-eosin stain; original magnifications: A, ×4; B, ×10.)

photodistributed areas on the hands (5 cases), arms (4 cases), legs (6 cases), and trunk (2 cases).

In 4 cases, PD-1 inhibitor therapy was discontinued shortly after the development of KAs. Treatment strategies include topical and intralesional steroids, cryotherapy, imiquimod, and curettage. Although systemic retinoids are first-line therapy for eruptive KAs associated with syndromes, their side-effect profile and potential interactions make them a less suitable choice for patients with metastatic cancer treated with immunotherapy. Notably, all of our patients’ KAs resolved within 8 weeks of initial presentation, without intervention, and while nivolumab therapy was continued. Similarly, Fujimura et al have recently reported a case of eruptive KAs associated with nivolumab resolving without intervention within 6 weeks, highlighting the transient nature of PD-1 inhibitor-associated eruptive KAs.

Several reported cases noted KAs to occur in the setting of recent or concomitant lichenoid skin toxicity or bullous pemphigoid-like disease,
| Reference          | Age y/sex | PD-1 inhibitor | Malignancy          | Time to onset of KAs | Distribution of KAs | PD-1 inhibitor discontinued? | Therapy and response                                      | Other dermatologic adverse events |
|--------------------|-----------|----------------|---------------------|----------------------|---------------------|-----------------------------|----------------------------------------------------------|----------------------------------|
| Bandino et al       | 73/M      | Pembrolizumab   | Metastatic melanoma | After sixth infusion (4 mo) | Bilateral lower extremities | Yes                         | Doxycycline and niacinamide for concurrent bullous pemphigoid-like eruption; KAs regressed spontaneously | Bullous pemphigoid-like eruption |
| Bandino et al       | 90/M      | Nivolumab, previously pembrolizumab | Metastatic melanoma | 6 mo after initiation of PD-1 inhibitor | Trunk | Yes | Electrodessication and curettage | Bullous pemphigoid-like eruption |
| Freites-Martinez et al | M   | Pembrolizumab   | Metastatic melanoma | 18 mo | Extremities | No | Clobetasol ointment, intralesional triamcinolone, cryotherapy; Complete response after 1 mo | Lichenoid skin reaction |
| Freites-Martinez et al | F   | Pembrolizumab   | Metastatic melanoma | 13 mo | Legs | No | Clobetasol ointment, intralesional triamcinolone, cryotherapy; Complete response after 1 mo | None |
| Freites-Martinez et al | M   | Pembrolizumab   | Metastatic scalp SCC | 4 mo | Dorsal hands | No | Clobetasol ointment, intralesional triamcinolone; Complete response after 1 mo | Lichenoid skin reaction |
| Feldstein et al     | 78/F      | Nivolumab       | Metastatic anal SCC | 6 mo | Arms, legs, upper chest | Yes | Imiquimod; Complete response at 6 months | None |
| Feldstein et al     | 85/F      | Nivolumab       | Pancreatic cancer   | After fifth infusion (2 mo) | Dorsal hands and palms, lower legs | Yes | Cryotherapy; Complete response at 4 month follow up | None |
although an eruptive KA may occur as an isolated phenomenon, as the case reported here. Many reports noted a lichenoid or interface dermatitis seen on skin biopsy of KAs. Some suggest that the lichenoid milieu and the enhanced T-cell response caused by PD-1 inhibitors may encourage the development of KAs in predisposed individuals, although the mechanism is poorly understood.

We report a tenth case of eruptive KAs in association with PD-1 inhibitor therapy; in this case, KAs were transient and showed rapid resolution despite continuation of immunotherapy. Based on the cases reported to date, eruptive KAs may not be an indication to discontinue immunotherapy and may be treated conservatively. Given the increasing usage of PD-1 inhibitors to treat malignancies, dermatologists and oncologists should be aware of this troublesome, but usually self-limited adverse effect.

REFERENCES
1. Hwang SJ, Carlos G, Wakade D, et al. Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort. *J Am Acad Dermatol*. 2016;74:455-461.e1.
2. Lopez AT, Khanna T, Antonov N, Audrey-Bayan C, Geskin L. A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors. *Int J Dermatol*. 2018;57:664-669.
3. Curry JL, Tetzlaff MT, Nagarajan P, et al. Diverse types of dermatologic toxicities from immune checkpoint blockade therapy. *J Cutan Pathol*. 2017;44:158-176.
4. Freites-Martinez A, Kwong BY, Rieger KE, Coit DG, Colevas AD, Lacouture ME. Eruptive keratoacanthomas associated with pembrolizumab therapy. *JAMA Dermatol*. 2017;153:694-697.
5. Fujimura T, Lyu C, Tsukada A, Sato Y, Kambayashi Y, Aiba S. Eruptive keratoacanthoma with spontaneous regression arising from a cervical squamous cell carcinoma patient treated with nivolumab. *J Dermatol*. 2018. https://doi.org/10.1111/1346-8138.14684.
6. Bandino JP, Perry DM, Clarke CE, Marchell RM, Elston DM. Two cases of anti-programmed cell death 1-associated bullous pemphigoid-like disease and eruptive keratoacanthomas featuring combined histopathology. *J Eur Acad Dermatol Venereol*. 2017;31:e378-e380.
7. Feldstein SI, Patel F, Larsen L, Kim E, Hwang S, Fung MA. Eruptive keratoacanthomas arising in the setting of lichenoid toxicity after programmed cell death 1 inhibition with nivolumab. *J Eur Acad Dermatol Venereol*. 2018;32:e58-e59.
8. Bednarek R, Marks K, Lin G. Eruptive keratoacanthomas secondary to nivolumab immunotherapy. *Int J Dermatol*. 2018;57: e28-e29.